Evidence map›Paper›PMID 12730827›Full record

ArticleAmerican journal of human genetics2003

A novel class of tests for the detection of mitochondrial DNA-mutation involvement in diseases.

Fengzhu Sun, Jing Cui, Haralambos Gavras, Faina Schwartz

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2008
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Fengzhu SunMolecular and Computational Biology Program, Department of Biological Sciences, University of Southern California, Los Angeles, CA 90089, USA. fsun@hto.usc.edu
Jing Cui
Haralambos Gavras
Faina Schwartz
Boston University · USUniversity of Southern California · US

Funding

The Role of Mitochondrial Genes in HypertensionR01AG018412 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SCHWARTZ, FAINA · 2001 to 2009
$2.1M
STATISTICAL STUDIES OF MTDNA INVOLVEMENT IN DISEASESR29DK053392 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SUN, FENGZHU · 1998 to 2002
$348k
NIA NIH HHS R01 AG018412NIA NIH HHS R01 AG18412NIDDK NIH HHS R29 DK53392
6 · The paper itself

Abstract

We develop a novel class of tests to detect mitochondrial DNA (mtDNA)-mutation involvement in complex diseases by the study of affected pedigree members. For a pedigree, affected individuals are first considered and are then connected through their relatives. We construct a reduced pedigree from an original pedigree. Each configuration of a reduced pedigree is given a score, with high scores given to configurations that are consistent with mtDNA-mutation involvement and low scores given to configurations that are not consistent with mtDNA-mutation involvement. For many pedigrees, the weighted sum of scores of the pedigrees is calculated. The tests are formed by comparing the observed score with the expected score under the null hypothesis that only nuclear autosomal mutations are involved. We study the optimality of score functions and weights under the heterogeneity model without phenocopies. We also develop a method to estimate the contribution that mtDNA mutations make if they are involved under a heterogeneity model. Finally, we apply our methods to three data sets: Leber hereditary optic neuropathy, a disease that has been proved to be caused by mtDNA mutations; non-insulin-dependent diabetes mellitus (NIDDM); and hypertension (HTN). We find evidence of mtDNA-mutation involvement in all three diseases. The estimated fraction of patients with NIDDM due to mtDNA-mutation involvement is 22% (95% confidence interval [CI] 6%-38%). The fraction of patients with HTN potentially due to mtDNA-mutation involvement is estimated at 55% (95% CI 45%-65%).

Indexed as

Diabetes Mellitus, Type 2DNA, MitochondrialDNA Mutational AnalysisHumansHypertensionModels, GeneticOptic Atrophy, Hereditary, LeberPedigreeDNA, Mitochondrial

Identifiers

PMID12730827
PMCPMC1180311
OpenAlexW1981613679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.